Journal
NATURE REVIEWS NEPHROLOGY
Volume 14, Issue 12, Pages 767-781Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41581-018-0071-x
Keywords
-
Categories
Funding
- Swedish Research Council (VR) [602699, 2016-2075-5.1, 2016-04519]
- Deutsche Forschungsgemeinschaft (DFG) [CRC1149 A01]
- Swedish Research Council [2016-04519] Funding Source: Swedish Research Council
Ask authors/readers for more resources
Increasing evidence indicates an integral role for the complement system in the deleterious inflammatory reactions that occur during critical phases of the transplantation process, such as brain or cardiac death of the donor, surgical trauma, organ preservation and ischaemia-reperfusion injury, as well as in humoral and cellular immune responses to the allograft. Ischaemia is the most common cause of complement activation in kidney transplantation and in combination with reperfusion is a major cause of inflammation and graft damage. Complement also has a prominent role in antibody-mediated rejection (ABMR) owing to ABO and HL A incompatibility, which leads to devastating damage to the transplanted kidney. Emerging drugs and treatment modalities that inhibit complement activation at various stages in the complement cascade are being developed to ameliorate the damage caused by complement activation in transplantation. These promising new therapies have various potential applications at different stages in the process of transplantation, including inhibiting the destructive effects of ischaemia and/or reperfusion injury, treating ABMR, inducing accommodation and modulating the adaptive immune response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available